Drug Delivery System for Emodin Based on Mesoporous Silica SBA-15

Overview

Journal Nanomaterials (Basel)

Date 2018 May 15

PMID 29757198

Citations 14

Authors

Tamara Krajnovic

Danijela Maksimovic-Ivanic

Sanja Mijatovic

Dijana Draca

Katharina Wolf

David Edeler

Ludger A Wessjohann

Goran N Kaluderovic

Affiliations

Soon will be listed here.

Abstract

In this study mesoporous silica SBA-15 was evaluated as a vehicle for the transport of cytotoxic natural product emodin (EO). SBA-15 was loaded with different quantities of EO (SBA-15|EO1⁻SBA-15|EO5: 8⁻36%) and characterized by traditional methods. Several parameters (stabilities) and the in vitro behavior on tumor cell lines (melanoma A375, B16 and B16F10) were investigated. SBA-15 suppresses EO release in extremely acidic milieu, pointing out that EO will not be discharged in the stomach. Furthermore, SBA-15 protects EO from photodecomposition. In vitro studies showed a dose dependent decrease of cellular viability which is directly correlated with an increasing amount of EO in SBA-15 for up to 27% of EO, while a constant activity for 32% and 36% of EO in SBA-15 was observed. Additionally, SBA-15 loaded with EO (SBA-15|EO3) does not disturb viability of peritoneal macrophages. SBA-15|EO3 causes inhibition of tumor cell proliferation and triggers apoptosis, connected with caspase activation, upregulation of Bax, as well as Bcl-2 and Bim downregulation along with amplification of poly-(ADP-ribose)-polymerase (PARP) cleavage fragment. Thus, the mesoporous SBA-15 is a promising carrier of the water-insoluble drug emodin.

Citing Articles

Advances in nano drug delivery systems for enhanced efficacy of emodin in cancer therapy.

Ai Z, Liu B, Chen J, Zeng X, Wang K, Tao C Int J Pharm X. 2025; 9():100314.

PMID: 39834843 PMC: 11743866. DOI: 10.1016/j.ijpx.2024.100314.

Triphenyltin(IV) Carboxylates with Exceptionally High Cytotoxicity against Different Breast Cancer Cell Lines.

Predarska I, Saoud M, Morgan I, Lonnecke P, Kaluderovic G, Hey-Hawkins E Biomolecules. 2023; 13(4).

PMID: 37189343 PMC: 10136130. DOI: 10.3390/biom13040595.

Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells.

Krajnovic T, Pantelic N, Wolf K, Eichhorn T, Maksimovic-Ivanic D, Mijatovic S Materials (Basel). 2022; 15(14).

PMID: 35888494 PMC: 9320346. DOI: 10.3390/ma15145028.

The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.

Zhang Q, Chen W, Sun X, Qian D, Tang D, Zhang L Int J Biol Sci. 2022; 18(8):3498-3527.

PMID: 35637953 PMC: 9134920. DOI: 10.7150/ijbs.70447.

Hydrogenation of alkyl-anthraquinone over hydrophobically functionalized Pd/SBA-15 catalysts.

Wang L, Zhang Y, Ma Q, Pan Z, Zong B RSC Adv. 2022; 9(59):34581-34588.

PMID: 35530007 PMC: 9074174. DOI: 10.1039/c9ra07351e.

References

Sarosiek K, Chi X, Bachman J, Sims J, Montero J, Patel L . BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell. 2013; 51(6):751-65. PMC: 4164233. DOI: 10.1016/j.molcel.2013.08.048. View

Mijatovic S, Maksimovic-Ivanic D, Radovic J, Miljkovic D, Harhaji L, Vuckovic O . Anti-glioma action of aloe emodin: the role of ERK inhibition. Cell Mol Life Sci. 2005; 62(5):589-98. PMC: 11365865. DOI: 10.1007/s00018-005-4425-8. View

Tao Z, Toms B, Goodisman J, Asefa T . Mesoporous silica microparticles enhance the cytotoxicity of anticancer platinum drugs. ACS Nano. 2010; 4(2):789-94. DOI: 10.1021/nn9015345. View

Sun Y, Wang X, Zhou Q, Lu Y, Zhang H, Chen Q . Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo. Oncol Rep. 2014; 33(1):338-46. DOI: 10.3892/or.2014.3585. View

Chun-Guang W, Jun-Qing Y, Bei-Zhong L, Dan-Ting J, Chong W, Liang Z . Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol. 2009; 627(1-3):33-41. DOI: 10.1016/j.ejphar.2009.10.035. View

Slowing I, Vivero-Escoto J, Wu C, Lin V . Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008; 60(11):1278-1288. DOI: 10.1016/j.addr.2008.03.012. View

Guo H, Bu H, Luo J, Wei W, Liu D, Chen H . Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis. Int J Oncol. 2012; 40(6):1849-57. DOI: 10.3892/ijo.2012.1389. View

Bulatovic M, Maksimovic-Ivanic D, Bensing C, Gomez-Ruiz S, Steinborn D, Schmidt H . Organotin(IV)-loaded mesoporous silica as a biocompatible strategy in cancer treatment. Angew Chem Int Ed Engl. 2014; 53(23):5982-7. DOI: 10.1002/anie.201400763. View

Chaitanya G, Steven A, Prakash Babu P . PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal. 2010; 8:31. PMC: 3022541. DOI: 10.1186/1478-811X-8-31. View

10.

Subramaniam A, Shanmugam M, Ong T, Li F, Perumal E, Chen L . Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. Br J Pharmacol. 2013; 170(4):807-21. PMC: 3799595. DOI: 10.1111/bph.12302. View

11.

Chang Y, Lai T, Yu C, Chen H, Yang J, Chueh F . Emodin Induces Apoptotic Death in Murine Myelomonocytic Leukemia WEHI-3 Cells In Vitro and Enhances Phagocytosis in Leukemia Mice In Vivo. Evid Based Complement Alternat Med. 2011; 2011:523596. PMC: 3108103. DOI: 10.1155/2011/523596. View

12.

Sevcovicova A, Bodnarova K, Loderer D, Imreova P, Galova E, Miadokova E . Dual activities of emodin--DNA protectivity vs mutagenicity. Neuro Endocrinol Lett. 2015; 35 Suppl 2:149-54. View

13.

Chen X, Yang Z, Sun R, Mo Z, Jin G, Wei F . Preparation of lung-targeting, emodin-loaded polylactic acid microspheres and their properties. Int J Mol Sci. 2014; 15(4):6241-51. PMC: 4013625. DOI: 10.3390/ijms15046241. View

14.

Muller S, Eckert I, Lutz W, Stopper H . Genotoxicity of the laxative drug components emodin, aloe-emodin and danthron in mammalian cells: topoisomerase II mediated?. Mutat Res. 1996; 371(3-4):165-73. DOI: 10.1016/s0165-1218(96)90105-6. View

15.

Krajnovic T, Kaluderovic G, Wessjohann L, Mijatovic S, Maksimovic-Ivanic D . Versatile antitumor potential of isoxanthohumol: Enhancement of paclitaxel activity in vivo. Pharmacol Res. 2016; 105:62-73. DOI: 10.1016/j.phrs.2016.01.011. View

16.

Liu A, Chen H, Wei W, Ye S, Liao W, Gong J . Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol Rep. 2011; 26(1):81-9. DOI: 10.3892/or.2011.1257. View

17.

Srinivas G, Babykutty S, Sathiadevan P, Srinivas P . Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev. 2006; 27(5):591-608. DOI: 10.1002/med.20095. View

18.

Ma Y, Weng S, Lin M, Lu C, Chiang J, Yang J . Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: roles of apoptotic cell death and LS1034 tumor xenografts model. Food Chem Toxicol. 2012; 50(5):1271-8. DOI: 10.1016/j.fct.2012.01.033. View

19.

Narayanan S, Jadhav A, Kadam V . Forced Degradation Studies of Aloe Emodin and Emodin by HPTLC. Indian J Pharm Sci. 2016; 77(6):795-8. PMC: 4778244. DOI: 10.4103/0250-474x.174997. View

20.

Vargas F, Fraile G, Velasquez M, Correia H, Fonseca G, Marin M . Studies on the photostability and phototoxicity of aloe-emodin, emodin and rhein. Pharmazie. 2002; 57(6):399-404. View